IMRX
USDImmuneering Corporation Class A Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$1.470
Haut
$1.490
Bas
$1.430
Volume
0.02M
Fondamentaux de l'Entreprise
Capitalisation Boursière
52.5M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.20M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.